Clinical Overview of Dalfampridine: An Agent With a Novel Mechanism of Action to Help With Gait Disturbances

Abstract Background Medication used to treat multiple sclerosis (MS) can be categorized as disease-modifying therapies, symptomatic therapies, or treatment of acute exacerbations. Dalfampridine is the first symptomatic therapy approved by the Food and Drug Administration to improve walking in patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2012-11, Vol.34 (11), p.2185-2194
Hauptverfasser:	Egeberg, Michael D., PharmD, Oh, Caleb Y., PharmD, Bainbridge, Jacquelyn L., PharmD, FCCP
Format:	Artikel
Sprache:	eng
Schlagworte:	4-aminopyridine 4-Aminopyridine - administration & dosage 4-Aminopyridine - adverse effects 4-Aminopyridine - economics 4-Aminopyridine - pharmacokinetics 4-Aminopyridine - therapeutic use Ampyra Animals Biological and medical sciences Clinical medicine dalfampridine Drug Costs Drug dosages Drug Interactions fampridine FDA approval Gait Gait - drug effects Gait Disorders, Neurologic - diagnosis Gait Disorders, Neurologic - drug therapy Gait Disorders, Neurologic - economics Gait Disorders, Neurologic - physiopathology Humans Internal Medicine Medical Education Medical sciences Molecular structure Multiple sclerosis Multiple Sclerosis - diagnosis Multiple Sclerosis - drug therapy Multiple Sclerosis - physiopathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Names Neurology Patient Selection Patients Pharmacokinetics Pharmacology. Drug treatments Potassium Potassium Channel Blockers - administration & dosage Potassium Channel Blockers - adverse effects Potassium Channel Blockers - economics Potassium Channel Blockers - pharmacokinetics Potassium Channel Blockers - therapeutic use Recovery of Function Risk Factors Seizures - chemically induced Treatment Outcome Walking
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!